Literature DB >> 21860053

Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study.

Stefan Klingberg1, Wolfgang Wölwer, Corinna Engel, Andreas Wittorf, Jutta Herrlich, Christoph Meisner, Gerhard Buchkremer, Georg Wiedemann.   

Abstract

Clinical studies on cognitive behavioral therapy (CBT) that include schizophrenia patients primarily on the basis of negative symptoms are uncommon. However, those studies are necessary to assess the efficacy of CBT on negative symptoms. This article first gives an overview of CBT on negative symptoms and discusses the methodological problems of selecting an adequate control group. Furthermore, the article describes a clinical study (the TONES-Study, ISRCTN 25455020), which aims to investigate whether CBT is specifically efficacious for the reduction of negative symptoms. This multicenter randomized clinical trial comparing CBT with cognitive remediation (CR) for control of nonspecific effects is depicted in detail. In our trial, schizophrenia patients (n = 198) participated in manualized individual outpatient treatments. Primary outcome is the negative syndrome assessed with the positive and negative syndrome scale, analyzed with multilevel linear mixed models. Patients in both groups moderately improved regarding the primary endpoint. However, against expectation, there was no difference between the groups after treatment in the intention to treat as well as in the per-protocol analysis. In conclusion, psychotherapeutic intervention may be useful for the reduction of negative symptoms. However, there is no indication for specific effects of CBT compared with CR.

Entities:  

Mesh:

Year:  2011        PMID: 21860053      PMCID: PMC3160126          DOI: 10.1093/schbul/sbr073

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  53 in total

1.  Cognitive remediation therapy for outpatients with chronic schizophrenia: a controlled and randomized study.

Authors:  Rafael Penadés; Rosa Catalán; Manel Salamero; Teresa Boget; Olga Puig; Joana Guarch; Cristóbal Gastó
Journal:  Schizophr Res       Date:  2006-06-05       Impact factor: 4.939

2.  The MATRICS initiative: developing a consensus cognitive battery for clinical trials.

Authors:  Michael F Green; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

3.  The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis.

Authors:  G Zimmermann; J Favrod; V H Trieu; V Pomini
Journal:  Schizophr Res       Date:  2005-09-01       Impact factor: 4.939

4.  Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.

Authors:  Mario Pfammatter; Ulrich Martin Junghan; Hans Dieter Brenner
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

Review 5.  Functional cognitive-behavioural therapy: a brief, individual treatment for functional impairments resulting from psychotic symptoms in schizophrenia.

Authors:  Corinne Cather
Journal:  Can J Psychiatry       Date:  2005-04       Impact factor: 4.356

Review 6.  The negative symptoms of schizophrenia: a cognitive perspective.

Authors:  Neil A Rector; Aaron T Beck; Neal Stolar
Journal:  Can J Psychiatry       Date:  2005-04       Impact factor: 4.356

7.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

8.  Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program.

Authors:  Wolfgang Wölwer; Nicole Frommann; Sabine Halfmann; Anja Piaszek; Marcus Streit; Wolfgang Gaebel
Journal:  Schizophr Res       Date:  2005-08-24       Impact factor: 4.939

9.  Integrated treatment ameliorates negative symptoms in first episode psychosis--results from the Danish OPUS trial.

Authors:  A Thorup; L Petersen; P Jeppesen; J Ohlenschlaeger; T Christensen; G Krarup; P Jørgensen; M Nordentoft
Journal:  Schizophr Res       Date:  2005-11-01       Impact factor: 4.939

Review 10.  Should schizophrenia be treated as a neurocognitive disorder?

Authors:  M F Green; K H Nuechterlein
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

View more
  28 in total

1.  The importance of cognitive processes for the integrative treatment of persons with schizophrenia.

Authors:  Mario Pfammatter; Hans Dieter Brenner; Ulrich Martin Junghan; Wolfgang Tschacher
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

2.  Pupillary Responses as a Biomarker of Diminished Effort Associated With Defeatist Attitudes and Negative Symptoms in Schizophrenia.

Authors:  Eric Granholm; Ivan Ruiz; Yuliana Gallegos-Rodriguez; Jason Holden; Peter C Link
Journal:  Biol Psychiatry       Date:  2015-09-15       Impact factor: 13.382

3.  [Evidence-based psychotherapy of schizophrenic psychoses].

Authors:  S Klingberg; A Wittorf
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

4.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

5.  The Vicious Cycle of Family Atmosphere, Interpersonal Self-concepts, and Paranoia in Schizophrenia-A Longitudinal Study.

Authors:  Klaus Hesse; Levente Kriston; Stephanie Mehl; Andreas Wittorf; Wolfgang Wiedemann; Wolfgang Wölwer; Stefan Klingberg
Journal:  Schizophr Bull       Date:  2015-04-29       Impact factor: 9.306

6.  Improvement in Negative Symptoms and Functioning in Cognitive-Behavioral Social Skills Training for Schizophrenia: Mediation by Defeatist Performance Attitudes and Asocial Beliefs.

Authors:  Eric Granholm; Jason Holden; Matthew Worley
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

7.  Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.

Authors:  Deepak C D'Souza; Rajiv Radhakrishnan; Edward Perry; Savita Bhakta; Nagendra M Singh; Richa Yadav; Danielle Abi-Saab; Brian Pittman; Santosh K Chaturvedi; Mahendra P Sharma; Morris Bell; Chittaranjan Andrade
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

Review 8.  Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.

Authors:  Esther Letícia Amorim Ribeiro; Tácio de Mendonça Lima; Marcio Eduardo Bergamini Vieira; Sílvia Storpirtis; Patricia Melo Aguiar
Journal:  Eur J Clin Pharmacol       Date:  2018-06-15       Impact factor: 2.953

9.  Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial.

Authors:  Pedro Sánchez; Javier Peña; Eneritz Bengoetxea; Natalia Ojeda; Edorta Elizagárate; Jesus Ezcurra; Miguel Gutiérrez
Journal:  Schizophr Bull       Date:  2013-05-18       Impact factor: 9.306

Review 10.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.